Table 2. LVEF assessmenta.
| Abbreviated trastuzumab | Conventional trastuzumab | |
|---|---|---|
| Baseline and post TH LVEF available – no. | 112 | 111 |
| Median post TH LVEF – no. | 61 | 61 |
| Post TH LVEF decline >10% – no. (%) | 12 (11) | 9 (8) |
| Post TH LVEF decline >10% and LVEF <LLN – no. (%) | 3 (3) | 1 (1) |
| Baseline and post AC LVEF available – no. | 95 | 104 |
| Median post AC LVEF – no. | 59 | 60 |
| Post AC LVEF decline >10% – no. (%) | 15 (16) | 13 (13) |
| Post AC LVEF decline >10% and LVEF <LLN – no. (%) | 3 (3) | 5 (5) |
| Baseline and post 1 year of treatmenta LVEF available – no. | 78 | 40 |
| Median post 1 year of treatment LVEF – no. | 62 | 63 |
| Post 1 year of treatment LVEF decline >10% – no. (%) | 13 (17) | 9 (23) |
| Post one year of treatment LVEF decline >10% and LVEF <LLN – no. (%) | 1 (1) | 2 (5) |
Abbreviation: LVEF=left ventricular ejection fraction.
a
Timepoint for Abbreviated trastuzumab Arm is 1 year post AC. Timepoint for conventional trastuzumab Arm is one year after completion of maintenance trastuzumab.